AA
NBIX icon

Ancora Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Ancora Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000
Closed -$126K – 2020
2025
Q2 		$126K Hold
1,000
– – ﹤0.01% 825
2025
Q1 		$111K Hold
1,000
– – ﹤0.01% 834
2024
Q4 		$137K Hold
1,000
– – ﹤0.01% 798
2024
Q3 		$115K Hold
1,000
– – ﹤0.01% 795
2024
Q2 		$138K Buy
+1,000
New +$137K ﹤0.01% 753
2022
Q3 		– Sell
-21
Closed -$2K – 2126
2022
Q2 		$2K Buy
+21
New +$1.94K ﹤0.01% 1958
2021
Q3 		– Sell
-43
Closed -$4K – 2270
2021
Q2 		$4K Buy
+43
New +$4.12K ﹤0.01% 1742

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ancora Advisors's NBIX Position: Q3 2025 in Review

Ancora Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 1,000 shares — an estimated $126K sold.

Ancora Advisors first reported a position in NBIX in Q2 2021 and held it in 7 quarters. The position peaked at $138K in Q2 2024. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Ancora Advisors reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Ancora Advisors sold 1,000 Neurocrine Biosciences shares in Q3 2025, an estimated $126K.
  • Ancora Advisors first reported a position in Neurocrine Biosciences in Q2 2021 and held it in 7 quarters.
  • Ancora Advisors's Neurocrine Biosciences position peaked at $138K in Q2 2024.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Ancora Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.